KXV01 clinical trials
How each study uses KXV01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KXV01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- KXV01 TCR Lentinvivo Injection
- 5
Studies by the year they started
5 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2025 | 4 |
| 2026 | 1 |
Who runs them
Industry 3 · Other 2
TCRx Therapeutics Co.Ltd (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · The First Hospital of Jilin University (1)
Often tested with
Tested in the same studies.
Izalontamab brengitecan (1) · CVL006 (1) · MT027 (1) · QH101 (1) · META10 (1) · TAEST1901 (1) · TCN 201 (1) · Base Edited Natural Killer Cells NK510 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test KXV01.
- Dec 2026Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid TumorsPhase 1 · The First Hospital of Jilin University
- Dec 2026Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid TumorsPhase 1 · TCRx Therapeutics Co.Ltd
- Dec 2026Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid TumorsPhase 1 · TCRx Therapeutics Co.Ltd
Studies
Open first, then newest update. How each study uses KXV01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid TumorsRecruitingPhase 1TCRx Therapeutics Co.LtdNCT07196579Written as KXV01 TCR Lentinvivo Injection
- Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid TumorsRecruitingPhase 1TCRx Therapeutics Co.LtdNCT07275853Written as KXV01 TCR Lentinvivo Injection
- KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)RecruitingPhase 1TCRx Therapeutics Co.LtdNCT07596693Written as KXV01 TCR Lentinvivo Injection
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07307053Written as KXV01 TCR Lentinvivo Injection
- Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid TumorsNot yet recruitingPhase 1The First Hospital of Jilin UniversityNCT07207681Written as KXV01 TCR Lentinvivo Injection
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
- Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid TumorsOct 26, 2026NCT07196579
- Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid TumorsOct 26, 2026NCT07275853